@entity146 , especially @entity1316 in @entity1 and adolescent are serious problem of all over the world in the field of @entity1 and adolescent psychiatry. In the recent years @entity1316 occur in the earlier age. The prevalence of @entity308 ( @entity308 ) is about 1-2% in preadolescent @entity1 and 3-8% in adolescents. When the @entity308 is not treated there is a big risk of worsening of symptoms, risk of suicide and development of @entity74 . The quality of life of the @entity1 and its family is decreasing in the whole view. The molecular basis of @entity308 is not well known. The main pathomechanism of @entity308 is in noradrenergic, serotonergic and dopaminergic pathway dysregulation, nutition factors, which can influence structure and metabolism of lipids. It was found decreased level of omega 3 fatty aids (FA), increased ratio of omega 6/omega 3 FA in the serum and in erythrocyte membrane. It is supposed that the oxidative neuronal injury can be prevented by dietary supplementation of antioxidants and that membrane phospholipids can be repaired by dietary supplementation of @entity1718 . @entity9539 may also participate in modulation of membrane fluidity, which influences the transmission of neurotransmitters. The membrane fluidity is affected by the ratio of phospholipids to free @entity165 . In addition, activation of the inflammatory response was found in @entity308 @entity1 through increased production of pro-inflammatory cytokines ( @entity1356 , @entity650 , @entity379 , @entity310 ) and @entity1813 ( @entity1421 ) in blood and cerebrospinal fluid. This results in increased lipid peroxidation and degradation of @entity1474 , which may result in increased oxidative stress. @entity9539 also stimulate anti-inflammatory cytokines ( @entity688 ) or inhibit the cyclooxygenase, platelet aggregation and formation of @entity1813 . The potential molecular mechanisms will be discussed.

@entity146 and XXXX .

@entity1 :: ('9606', 'Species') :: ['patient', 'child', 'children', 'patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity308 :: ('MESH:D003866', 'Disease') :: ['major depression', 'MD', 'depressive'] @entity146 :: ('MESH:D001523', 'Disease') :: ['Psychiatric disorders'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b'] @entity310 :: ('7124', 'Gene') :: ['TNF-alpha'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['prostaglandin E2'] @entity1474 :: ('MESH:D005231', 'Chemical') :: ['polyunsaturated fatty acids'] @entity1316 :: ('MESH:D019964', 'Disease') :: ['mood disorders'] @entity688 :: ('3586', 'Gene') :: ['IL-10'] @entity379 :: ('3458', 'Gene') :: ['interferon gamma'] @entity74 :: ('MESH:D030342', 'Disease') :: ['comorbid disorders'] @entity9539 :: ('MESH:D015525', 'Chemical') :: ['Omega-3 fatty acids'] @entity1813 :: ('MESH:D015777', 'Chemical') :: ['eicosanoids'] @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity9539 :: (MESH:D015525,Chemical) :: ['omega-3 fatty acids']
